Summit Therapeutics Future Growth

Future criteria checks 0/6

Summit Therapeutics wird voraussichtlich ein Umsatzwachstum verzeichnen at 77.1% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	20.9%
Revenue growth rate	77.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 Mar 2024

Recent future growth updates

No updates

Recent updates

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Earnings and Revenue Growth Forecasts

NasdaqGM:SMMT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10	N/A	-308	-249	1
12/31/2025	N/A	N/A	-216	-172	1
12/31/2024	N/A	N/A	-156	-120	1
12/31/2023	N/A	-615	-552	-77	N/A
9/30/2023	N/A	-598	-52	-52	N/A
6/30/2023	0	-598	-46	-46	N/A
3/31/2023	0	-600	-36	-36	N/A
12/31/2022	1	-79	-42	-42	N/A
9/30/2022	1	-87	-57	-56	N/A
6/30/2022	2	-85	-72	-71	N/A
3/31/2022	2	-93	-72	-71	N/A
12/31/2021	2	-89	-73	-73	N/A
9/30/2021	2	-75	-72	-71	N/A
6/30/2021	1	-73	-65	-64	N/A
3/31/2021	1	-64	-64	-64	N/A
12/31/2020	1	-53	-49	-48	N/A
9/30/2020	1	-51	-49	-49	N/A
6/30/2020	1	-40	-38	-37	N/A
3/31/2020	-5	-31	-18	-18	N/A
12/31/2019	1	-32	-23	-23	N/A
10/31/2019	26	-28	-24	-23	N/A
7/31/2019	24	-27	-20	-19	N/A
4/30/2019	72	12	-24	-24	N/A
1/31/2019	57	11	-35	-35	N/A
10/31/2018	70	2	-36	-36	N/A
7/31/2018	72	11	-45	-45	N/A
4/30/2018	27	-29	-19	-19	N/A
1/31/2018	20	-29	-21	-21	N/A
10/31/2017	15	-18	N/A	-20	N/A
7/31/2017	12	-23	N/A	31	N/A
4/30/2017	5	-27	N/A	14	N/A
1/31/2017	3	-27	N/A	15	N/A
10/31/2016	1	-29	N/A	15	N/A
7/31/2016	1	-33	N/A	-26	N/A
4/30/2016	1	-32	N/A	-29	N/A
1/31/2016	2	-29	N/A	-24	N/A
10/31/2015	2	-25	N/A	-23	N/A
7/31/2015	3	-20	N/A	-20	N/A
4/30/2015	3	-19	N/A	-21	N/A
1/31/2015	3	-17	N/A	-17	N/A
10/31/2014	3	-17	N/A	-16	N/A
7/31/2014	4	-17	N/A	-16	N/A
4/30/2014	4	-13	N/A	-11	N/A
1/31/2014	3	-10	N/A	-10	N/A
10/31/2013	0	-8	N/A	-6	N/A
7/31/2013	2	-6	N/A	-5	N/A
4/30/2013	2	-7	N/A	-5	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SMMT über der Sparquote liegt (2.3%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SMMT schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SMMT in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: SMMT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: SMMT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SMMT in 3 Jahren voraussichtlich hoch sein wird

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Summit Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole

Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Summit Therapeutics to join Russell 3000 Index

Summit Therapeutics Inc. Announces Selected A New Preclinical Candidate, SMT026738

Summit Therapeutics Inc. Elects Dr. Michael Wang as Member of the Board

Summit Therapeutics Inc. Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics Inc. announced that it has received $50 million in funding from Polar Capital LLP and other investors

Summit Therapeutics Inc. announced that it expects to receive $50 million in funding

Summit Therapeutics Inc. Publishes Data from Its Phase 2 Clinical Trial of Ridinilazole Evaluating the Effects of A Narrow-Spectrum (Ridinilazole) or Broad-Spectrum Antibiotic

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies